October 1, 2020 05:23 PM EDTUpdated October 2, 06:34 AM
Financing
R&D

Is the fu­ture of di­a­betes drugs in dual GIP and GLP-1 in­cretin re­cep­tor ag­o­nists? That's the $47M ques­tion for Car­mot

Max Gelman

Senior Editor

Near­ly three years af­ter clos­ing its Se­ries B, Car­mot Ther­a­peu­tics has re­turned to the fundrais­ing well with a new round. And this time they brought …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times